Market Newsdesk

The Company is planning to file the S-1 Registration Statement by May.

LAS VEGAS, NV, April 07, 2021 (GLOBE NEWSWIRE) — via NewMediaWire – Ameritek Ventures, Inc. (OTC: ATVK), a company focused on developing and launching innovative technology, manufacturing products for businesses and governments, announced today its FlexFridge prototype will be submitted to UL Certification in May 2021. The FlexFridge size has increased to 6 cubic feet. The software for the FlexFridge is nearly done. 

Ameritek Ventures, Inc. has engaged a PCAOB auditor and works with a Canadian law firm that works on both United States Registration Statement and Canadian stock exchange listing application to file an S-1 registration statement. The S-1 registration statement will make Ameritek Ventures an SEC reporting company that needs to be uplisted to OTCQB to attract broker-dealers and recommend their clients about our company. 

About Ameritek Ventures 

Ameritek Ventures is a group of companies that provides various world-class software and hardware products and services beneficial to businesses, organizations, and governments. We manufacture and innovate advanced technological developments in the medical industry, portable medical use mini-fridge. Ameritek Ventures explores augmented reality technology with Augmum, Inc. Augmum, Inc., a subsidiary of Ameritek Ventures, Inc., is a glove and glasses augmented reality technology manufacturer. Augmum creates motion-tracking robotic hands, touch-sensing gloves, and virtual-reality glasses using machine learning systems, haptic technology, and augmented technology to control its six-axis robotic arm. 

Safe Harbor

This is the “Safe Harbor” statement under the Private Securities Litigation Reform Act of 1995: Certain statements contained in this press release are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by the use of forward-looking words such as “may,” “expect,” “intend,” “estimate,” “anticipate,” “believe” and “continue” (or the negation thereof) or similar terminology. Such forward-looking statements are subject to risks, uncertainties and other factors that could cause actual results to differ materially from future results or those implied by such forward-looking statements. Investors are cautioned that no forward-looking statement is a guarantee of future performance and that actual results may differ materially from those contemplated by such forward-looking statements. Ameritek Ventures assumes no obligation and has no intention of updating these forward-looking statements. It has no obligation to update or correct information prepared by third parties that are not paid for by Ameritek Ventures. Investors are encouraged to review Ameritek Ventures’ public filings on SEC.gov and otcmarkets.com, including its unaudited and audited financial statements and its OTC market filings, which contain general business information about the company’s operations, results of operations, and risks associated with the company and its operations.

CONTACT: For more information, please contact the following:

Investor Relations
https://twitter.com/AmeritekInfo
[email protected]
(312) 239-3574
https://www.ameritekventures.com/

ATLANTA, April 07, 2021 (GLOBE NEWSWIRE) —

• Beta Technologies’ electric Vertical Takeoff and Landing (eVTOL) aircraft to land on-property at UPS facilities in small and mid-size markets.
• Enhances UPS network flexibility, benefits healthcare providers and small and medium-sized businesses.
• Flexible, sustainable solution to reduce air network emissions; recharging station can also be used with electric-powered ground vehicles.

UPS
(NYSE:UPS), together with its UPS Flight Forward subsidiary, plans to purchase electric Vertical Takeoff and Landing (eVTOL) aircraft from Beta Technologies (BETA) to augment its air service for select small and mid-size markets. These aircraft will take off and land on-property at UPS facilities in a whisper-quiet fashion, reducing time-in-transit, vehicle emissions, and operating cost.

The BETA aircraft’s 1,400-pound cargo capacity is ideally suited to more quickly and sustainably transport time-sensitive deliveries that would otherwise fly on small fixed-wing aircraft. UPS’s use of the aircraft will benefit healthcare providers, thousands of small and medium-sized businesses, and other companies in smaller communities. With a 250-mile range and cruising speed of up to 170 miles per hour, UPS will be able to plan a series of short routes, or one long route, on a single charge to meet customers’ needs.

“This is all about innovation with a focus on returns for our business, our customers, and the environment,” said UPS Chief Information and Engineering Officer Juan Perez. “These new aircraft will create operational efficiencies in our business, open possibilities for new services, and serve as a foundation for future solutions to reduce the emissions profile of our air and ground operation.”

The aviation industry is focusing on small aircraft, which UPS uses to serve many small and medium-sized communities, to develop groundbreaking, sustainable electric-powered aircraft. BETA’s aircraft has four fixed vertical lift propellers and one pusher propeller for forward flight. It can charge in an hour or less, and produces zero operational emissions.

“We’re combining simple, elegant design and advanced technology to create a reliable aircraft with zero operational emissions that will revolutionize how cargo moves,” said BETA founder and CEO Kyle Clark. “By utilizing vertical takeoffs and landings, we can turn relatively small spaces at existing UPS facilities into a micro air feeder network without the noise or operating emissions of traditional aircraft.”

UPS has also reserved BETA’s recharging station for a seamless and fully integrated electric aviation system. The BETA charging station helps ensure safe and rapid charging of the aircraft in under one hour, and facilitates a quick turn for the loading and unloading of cargo. The charging station also offers the aircraft’s batteries a second life cycle.

After the batteries’ first life cycle in the aircraft concludes, they can be fitted to the charging stations to recharge the aircraft’s onboard batteries as well as UPS’s fleet of electric ground vehicles. UPS currently operates more than 12,000 alternative fuel and advanced technology vehicles, and announced a commitment to purchase up to 10,000 Arrival electric vehicles.

BETA’s aircraft are designed to someday operate autonomously as technologies and regulations are established. UPS Flight Forward received the first U.S. Federal Aviation Administration (FAA) Part 135 Standard air carrier certification to operate a drone airline, and is operating daily revenue-generating flights with drones. The FAA certification also enables UPS Flight Forward to fly payloads of up to 7,500 lbs. either with an operator or autonomously.

Last month, BETA advanced to the next phase of flight testing, completing an interstate flight from its Plattsburgh, NY test facility to its Burlington, Vt. headquarters. In accordance with FAA protocols for experimental aircraft to fly beyond its home airport, BETA had to complete rigorous testing to ensure reliable and predictable behavior of the aircraft. In the same week, the company set a new personal-best in range while also reaching 8,000 feet in altitude.

The first ten BETA aircraft are scheduled to begin arriving in 2024, with an option to purchase up to 150 of the aircraft.

Editor’s note: Multimedia assets are available on UPS Brand Central.

About UPS

UPS (NYSE: UPS) is one of the world’s largest package delivery companies with 2020 revenue of $84.6 billion, and provides a broad range of integrated logistics solutions for customers in more than 220 countries and territories. The company’s more than 540,000 employees embrace a strategy that is simply stated and powerfully executed: Customer First. People Led. Innovation Driven. UPS is committed to being a steward of the environment and positively contributing to the communities we serve around the world. UPS also takes a strong and unwavering stance in support of diversity, equity and inclusion. The company can be found on the Internet at www.ups.com, with more information at www.stories.ups.com and www.investors.ups.com.

Contact: UPS Media Relations
              404-828-7123
              [email protected]

PALO ALTO, Calif., April 07, 2021 (GLOBE NEWSWIRE) — Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today announced that it will be hosting a key opinion leader (KOL) meeting on bioconjugation and CDK9 inhibitors for the treatment of hematologic and solid tumors on Friday, April 16, 2021 at 12:00 PM ET.

The event will feature presentations by KOLs Brian Druker, M.D., Knight Cancer Institute, and Anthony W. Tolcher, M.D., NEXT Oncology™. Dr. Tolcher will discuss tackling normal tissue toxicity from antibody-drug conjugates (ADCs) and Dr. Druker will discuss CDK9 in hematologic malignancies. Drs. Druker and Tolcher will be available to answer questions following the formal presentations.

Vincerx’s management team will discuss its poster titled, “A novel small molecule drug conjugate -αvβ3 integrin antagonist linked to a cytotoxic camptothecin derivative- for the treatment of multiple cancer types,” which will be presented at the upcoming American Association for Cancer Research (AACR) Annual Meeting, as well as the Company’s bioconjugation platform. Vincerx’s preclinical bioconjugation platform seeks to address the current limitations of small-molecule and antibody-drug conjugates in oncology and consists of VIP236, a small molecule drug conjugate (SMDC) targeting advanced and metastatic cancer, as well as VIP943 and VIP924, two ADCs targeting hematologic tumors.

To register for the webinar, please click here.

KOLs


Brian Druker, M.D., is the director of the Knight Cancer Institute, associate dean for oncology of the OHSU School of Medicine and the JELD-WEN Chair of Leukemia Research. His research is focused on translating the knowledge of the molecular pathogenesis of cancer into specific therapies and investigating the optimal use of these molecularly targeted agents. He performed preclinical studies that led to the development of imatinib (Gleevec) for chronic myeloid leukemia (CML) and then spearheaded the highly successful clinical trials of imatinib, which led to FDA approval of the drug in record time. This work changed the life expectancy of patients with CML from an average of 3 to 5 years to a 95% five-year survival and has resulted in a paradigm-shift in cancer treatment from non-specific chemotherapy to highly targeted therapeutic agents. He is a member of the National Academy of Medicine, the National Academy of Sciences and, among numerous awards, is the recipient of the 2009 Lasker-DeBakey Clinical Medical Research Award, the 2012 Japan Prize in Healthcare and Medical Technology and the 2019 Sjöberg Prize.

Anthony W. Tolcher, M.D. is CEO and Founder of NEXT Oncology™, San Antonio and Austin, Texas, Phase I group that seeks to transform early clinical trials. NEXT Oncology’s mission is to accelerate the next breakthrough medicines for cancer and the vision is to be the most successful and respected Phase I program in oncology research. Dr. Tolcher served as President and Co- Founder of START LLC from 2009- 2018, one of the world’s largest Clinical Phase I and early drug development operations in cancer medicine with 5 locations in San Antonio Texas; Grand Rapids, Michigan; Madrid Spain; and Shanghai China.

Dr. Tolcher is a medical oncologist who has over 25 years’ experience in early drug development and clinical trials. He has been involved in many of the initial phase I studies of new agents that subsequently were FDA approved for the treatment of cancer including pembrolizumab (Keytruda), copanlisib (Aliqopa), trastuzumab emtansine (Kadcyla), regorafenib (Stivarga), liposomal vincristine (Marqibo), cabazitaxel (Jevtana), carfilzomib (Kyprolis), gefitinib (Iressa), erlotinib (Tarceva), and eribulin (Halaven). He is currently the principal investigator on 40 phase I clinical studies, is a reviewer for the Journal of Clinical Oncology, Clinical Cancer Research, and Annals of Oncology. He has chaired the Developmental Therapeutics Review Committee for the American Association of Clinical Oncology Annual Scientific Program. Dr. Tolcher has over 100 peer-reviewed publications in scientific journals including Nature, Proceedings of the National Academy of Sciences (USA), Journal of Clinical Oncology, and Clinical Cancer Research, as well as an author of nine book chapters

About Vincerx Pharma, Inc.

Vincerx Pharma, Inc. (Vincerx) is a recently formed clinical-stage life sciences company focused on leveraging its extensive development and oncology expertise to advance new therapies intended to address unmet medical needs for the treatment of cancer. Vincerx’s executive team has assembled a management team of biopharmaceutical experts with extensive experience in building and operating organizations that develop and deliver innovative medicines to patients. Vincerx’s current pipeline is derived from an exclusive license agreement with Bayer and includes a clinical-stage and follow-on small molecule drug program and a preclinical stage bioconjugation/next-generation antibody-drug conjugate platform. For more information, please visit www.vincerx.com.

Cautionary Statement

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended, that are intended to be covered by the “safe harbor” created by those sections. Forward-looking statements, which are based on certain assumptions and describe future plans, strategies, expectations and events, can generally be identified by the use of forward-looking terms such as “believe,” “expect,” “may,” “will,” “should,” “would,” “could,” “seek,” “intend,” “plan,” “goal,” “project,” “estimate,” “anticipate” or other comparable terms. All statements other than statements of historical facts included in this press release are forward-looking statements. Forward-looking statements include, but are not limited to: Vincerx’s business model, pipeline, strategy, timeline and product candidates. Forward-looking statements are neither historical facts nor assurances of future performance or events. Instead, they are based only on current beliefs, expectations and assumptions regarding future business developments, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Forward-looking statements are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control.

Actual results, conditions and events may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause actual results, conditions and events to differ materially from those indicated in the forward-looking statements include, but are not limited to: general economic, financial, legal, political and business conditions and changes in domestic and foreign markets; the potential effects of the COVID-19 pandemic; risks associated with preclinical or clinical development conducted prior to Vincerx’s in-licensing; failure to realize the anticipated benefits of the business combination with LifeSci Acquisition Corp.; failure to realize the benefits of Vincerx’s license agreement with Bayer; risks related to the rollout of Vincerx’s business and the timing of expected business milestones; changes in the assumptions underlying Vincerx’s expectations regarding its future business or business model; Vincerx’s ability to develop and commercialize product candidates; the availability and uses of capital; the effects of competition on Vincerx’s future business; and the risks and uncertainties set forth in Forms 10-K, 10-Q and 8-K filed with or furnished to the SEC from time to time by Vincerx. Forward -looking statements speak only as of the date hereof, and Vincerx disclaims any obligation to update any forward-looking statements.

Contacts

Bruce Mackle
LifeSci Advisors, LLC
646-889-1200
[email protected]

 

MOBILE, AL, April 07, 2021 (GLOBE NEWSWIRE) — via NewMediaWire — Deuce Drone LLC, a developer of last mile package delivery services by drone, announced today that Mr. Ed Fienga, Brig. General, US Air Force (ret), has joined the company as its Chief Operating Officer.  Mr. Fienga brings 35 years of organizational and technology growth leadership to the Deuce Drone team.

Mr. Fienga has spent the past five years following his retirement from the Air Force as a partner growing a small company focused on managing business processes, logistics and supply chain systems within the national defense and government sectors.  Prior to that, he spent his last decade in the Air Force leading Air, Space and Cyberspace organizations at the Installation, Major Command and Headquarters Air Force levels.

Ed joins Deuce Drone to provide daily leadership for the launch of last mile package delivery services in 2021.  His specific duties will include building a delivery service team to operate under the FAA’s updated Part 107 rules, developing and launching Part 107 compliant delivery routes, expanding customers, and generating revenue.  In addition, Mr. Fienga will take a direct role in completing our Part 135 submission to allow full, automated, beyond line-of-sight drone delivery operations as an air carrier.

“We are excited to have Ed join our growing team,” said Rhett Ross, CEO of Deuce Drone.  “His experience in overseeing complex, technology programs as a strategic leader in the Air Force, identifying program requirements and then advocating for the necessary resources to bring them to fruition is directly applicable to the complexity of launching safe, last mile package delivery by drones.” 

Deuce Drone’s impressive team of aerospace, autonomous vehicle, construction, and technology experts is leading the way in e-commerce last mile fulfillment technology and services. The company is responsible for the design of artificial intelligence and software systems to support automated drone flight management, automated retail center package logistic systems, automated drone landing, recharging and loading systems, as well as overall drone fleet logistics management.  The foundation of Deuce Drone’s philosophy is to focus on technology solutions that are safe, community responsible and regulatorily compliant while bringing value and quality of life improvements to our full range of customers.

About Deuce Drone:

Deuce Drone is developing technology and services to provide last mile delivery for “brick and mortar” retailers by enabling drone shipment from existing stores.  Leveraging clients’ current infrastructure, we design, build, and operate drone delivery systems, transforming retail stores into customer fulfillment centers.  Deuce Drone, an (OTC: NCPL) portfolio company, provides a cost-effective, technology-driven solution for same-day delivery that allows retailers to compete with major e-commerce players. 

Rhett Ross
251-445-5370
[email protected]

PORTLAND, Maine, April 07, 2021 (GLOBE NEWSWIRE) — ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and productivity of dairy and beef cattle, today announced preliminary, unaudited sales results for the first quarter ended March 31, 2021.

Beginning with the first quarter of 2020, the Company has been providing a preliminary look at the top line results early in the reporting period. The Company expects to provide this prompt, preliminary report on product sales until further notice going forward.

“We expect to report a 16%, or $791,000, decrease in total product sales to approximately $4.1 million during the quarter ended March 31, 2021 versus the same period of the prior year, during which our sales benefitted from a higher level of beginning inventory,” commented Michael F. Brigham, President and CEO of ImmuCell. “This level of sales represents nearly 100% of our quarterly production capacity, underscoring the importance of the investment we are making to increase our annual production capacity from $16.5 million to $23 million, which is on schedule to be completed by June 30^th. These capacity estimates are subject to biological yield variance, product format mix, selling price and other factors.”

Mr. Brigham added, “We anticipated a decrease in sales for the quarter, as first publicly projected on February 22, 2021, and the amount of the decrease is consistent with what we projected in our Form 10-K filing on March 30, 2021. We expect that we can manage through this transitional drop in sales to end the year with positive sales growth year over year.”

“Due to strong demand, the backlog of orders worth approximately $1.8 million as of December 31, 2020 increased to approximately $3 million as of March 31, 2021,” Mr. Brigham concluded. “Given that some orders were cancelled during the first quarter and additional orders may still be cancelled, the amount of the order backlog is not directly comparable from period to period, but it does provide some indication of the amount of unmet demand for our product.”

Conference Call:


The Company will host a conference call on Friday, May 14, 2021 to discuss the financial results for the quarter ended March 31, 2021. Interested parties can access the conference call by dialing (844) 855-9502 (toll free) or (412) 317-5499 (international) at 9:00 AM ET. A teleconference replay of the call will be available for seven days at (877) 344-7529 (toll free) or (412) 317-0088 (international), utilizing confirmation #10154478. Investors are encouraged to review the Company’s updated Corporate Presentation slide deck that provides an overview of the Company’s business and is available under the “Investors” tab of the Company’s website at www.immucell.com, or by request to the Company.

About ImmuCell:


ImmuCell Corporation’s (Nasdaq: ICCC) purpose is to create scientifically-proven and practical products that improve the health and productivity of dairy and beef cattle. ImmuCell manufactures and markets First Defense^®, providing Immediate Immunity™ to newborn dairy and beef calves, and is in the late stages of developing Re-Tain™, a novel treatment for subclinical mastitis without a milk discard requirement that provides an alternative to traditional antibiotics. Press releases and other information about the Company are available at: http://www.immucell.com.

Contacts:

Michael F. Brigham, President and CEO ImmuCell Corporation (207) 878-2770 Joe Diaz, Robert Blum and Joe Dorame Lytham Partners, LLC (602) 889-9700 [email protected]

Cautionary Note Regarding Forward-Looking Statements (Safe


Harbor


Statement):

This Press Release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements include, but are not limited to, any statements relating to: our plans and strategies for our business; projections of future financial or operational performance; the timing and outcome of pending or anticipated applications for regulatory approvals; factors that may affect the dairy and beef industries and future demand for our products; the extent, nature and duration of the COVID-19 pandemic and its consequences, and their direct and indirect impacts on the Company’s production activities, operating results and financial condition and on the customers and markets the Company serves; the scope and timing of ongoing and future product development work and commercialization of our products; future costs of product development efforts; the estimated prevalence rate of subclinical mastitis and producers’ level of interest in treating subclinical mastitis given the current economic and market conditions; the expected efficacy of new products; estimates about the market size for our products; future market share of and revenue generated by current products and products still in development; our ability to increase production output and reduce costs of goods sold; the future adequacy of our own manufacturing facilities or those of third parties with which we have contractual relationships to meet demand for our products on a timely basis; the impacts of backlogs on customer relationships; the anticipated costs of (or time to complete) planned expansions of our manufacturing facilities and the adequacy of our funds available for these projects; the continuing availability to us on reasonable terms of third-party providers of critical products or services; the robustness of our manufacturing processes and related technical issues; estimates about our production capacity, efficiency and yield, which are highly subject to biological variability and the product format mix of our sales; the future adequacy of our working capital and the availability and cost of third-party financing; future regulatory requirements relating to our products; future expense ratios and margins; future compliance with bank debt covenants; costs associated with sustaining compliance with current Good Manufacturing Practice (cGMP) regulations in our current operations and attaining such compliance for the facility to produce the Nisin Drug Substance; our effectiveness in competing against competitors within both our existing and our anticipated product markets; the cost-effectiveness of additional sales and marketing expenditures and resources; anticipated changes in our manufacturing capabilities and efficiencies; the value of our net deferred tax assets; projections about depreciation expense and its impact on income for book and tax return purposes; anticipated market conditions; and any other statements that are not historical facts. Forward-looking statements can be identified by the use of words such as “expects”, “may”, “anticipates”, “aims”, “intends”, “would”, “could”, “should”, “will”, “plans”, “believes”, “estimates”, “targets”, “projects”, “forecasts”, “seeks” and similar words and expressions. In addition, there can be no assurance that future developments affecting us will be those that we anticipate. Such statements involve risks and uncertainties, including, but not limited to, those risks and uncertainties relating to difficulties or delays in development, testing, regulatory approval, production and marketing of our products (including the First Defense^® product line and Re-Tain™), competition within our anticipated product markets, customer acceptance of our new and existing products, product performance, alignment between our manufacturing resources and product demand (including the consequences of backlogs or excess inventory buildup), our reliance upon third parties for financial support, products and services, changes in laws and regulations, decision making and delays by regulatory authorities, currency values and fluctuations and other risks detailed from time to time in filings we make with the Securities and Exchange Commission (SEC), including our Quarterly Reports on Form 10-Q, our Annual Reports on Form 10-K and our Current Reports on Form 8-K. Such statements involve risks and uncertainties and are based on our current expectations, but actual results may differ materially due to various factors, including the risk factors summarized above.

Considers Offer of $8.50 per Share Grossly Insufficient

Believes a Conservative Sum of the Parts Value of the Stock is $17.43 per Share

Questions the Process That Led to the Announced Merger

NEW YORK, April 07, 2021 (GLOBE NEWSWIRE) — A group of stockholders of Leaf Group Ltd. (“LEAF” or the “Company”)(NYSE:LEAF), comprised of VIEX Opportunities Fund, LP –Series One, Osmium Capital, LP and Oak Investment Partners XI, Limited Partnership (together with their affiliates, “we” or the “Stockholder Group”), who beneficially own approximately 25% of the outstanding common stock of the Company, today issued the following statement in response to the proposed acquisition of LEAF by Graham Holdings Company (“Graham”):

“While we are generally supportive of a sale of the Company, we are concerned that the recently announced merger of the Company into Graham for $8.50 per share does not reflect the Company’s full and fair market value (the “Merger Transaction”). Specifically, we have concerns that the “shotgun style wedding” sale process for the entire Company in less than seven weeks was deeply flawed and not only crystalizes a significant conglomerate discount but also fails to compensate shareholders for a change of control premium. Based on figures reported in the Company’s most recent Annual Report on Form 10-K and estimates supported by sell-side analysts, we believe a conservative sum of the parts valuation of LEAF’s assets yields a price of $15.83 to $17.43 per share, comprising of the following elements:

• Net cash of $1.76 per share;¹
• Revenue from the Digital Marketplace segment, which grew 73% in fiscal 2020, is approximately $195 million, and at a 2x multiple, would yield $390M in a sale, or $10.89 per share;²
• Revenue from the Digital Media business is approximately $57 million, and at a 2-3x multiple, would yield $114 to $171 million in a sale, or $3.18 to $4.78 per share;³
• The Company has $269.7 million in net operating loss carry forwards that may substantially shield taxable income and represent significant potential value to the right acquirer, which we have valued at zero to be conservative.
• Total value = $15.83 to $17.43 per share.

Accordingly, LEAF’s proposed sale to Graham at $8.50 represents an estimated 50% discount⁴ to the existing haircut of 40% to 80% relative to its publicly traded peers. To starkly contrast this differential, if LEAF achieved a public peer multiple in its Digital Media and Digital Marketplace business of 5.5x and 8.8x sales, respectively, the value of the Company’s combined businesses would be nearly $1.68 billion or $46.86 per share. We acknowledge that the Company operates below peer profit margins and possesses other leadership challenges which need to be discounted and accounted for. Nonetheless, we are deeply concerned with the consideration proposed in the Merger Transaction.

We also have concerns with the process described in the Company’s press release announcing the Merger Transaction. In our view, contacting just ten additional financial and strategic buyers about their interest in acquiring Leaf Group following the receipt of a proposal from Graham to acquire the Company does not appear to be a broadly conducted sales process, particularly in light of the fact that the Board had received a nomination notice from the Stockholder Group seeking to replace three incumbent directors.

We intend to carefully review the Company’s proxy materials seeking approval of the Merger Transaction before determining how we plan to vote our shares. However, we urge the Board to proactively reengage with Graham to achieve a more equitable price for the benefit of all stockholders before filing preliminary proxy materials.”

About VIEX Capital Advisors

VIEX Capital Advisors, LLC is a firm focused on investing in small and mid-cap technology companies. VIEX seeks to work alongside management and company boards to identify and execute on opportunities to unlock value for the benefit of all stockholders.

About Osmium Partners

We seek to generate strong, risk-adjusted returns by investing in undervalued, small capitalization companies across equity markets. Our Osmium 8 research process is based on eight simple factors involving factors such as balance sheet strength, aligned interests, attractive reinvestment opportunities, a low valuation, and reasonable growth prospects. As engaged owners, we actively discuss corporate strategy and capital structure with management teams and boards of directors. We prefer to conduct these discussions in private, but we will publicly debate important items with all shareholders when appropriate.

About Oak Investment Partners

Oak Investment Partners was founded in 1978. Since that time, the firm has invested $9 billion in over 525 companies around the world, earning the trust of entrepreneurs with a senior team that delivers steady guidance, deep domain expertise and a consistent investment philosophy. We are involved in the formation of companies, fund spinouts of operating divisions and technology assets, and provide growth equity to mid- and late-stage private businesses and to public companies through PIPE investments. These companies are concentrated in the five major sectors that fuel the most disruptive growth in our world today: Information Technology, FinTech, Internet and Consumer, Healthcare Services, and Clean Energy.

CERTAIN INFORMATION CONCERNING THE PARTICIPANTS

VIEX Opportunities Fund, LP –Series One (“Series One”), Osmium Capital, LP (“Osmium Fund I”) and Oak Investment Partners XI, Limited Partnership (“Oak XI”), together with the participants named herein, intend to file a preliminary proxy statement and accompanying WHITE proxy card with the Securities and Exchange Commission (“SEC”) to be used to solicit votes for the election of their slate of director nominees and for a non-binding proposal to declassify the Board of Directors of Leaf Group Ltd., a Delaware corporation (the “Company”) at the Company’s 2021 annual meeting of stockholders.

SERIES ONE, OSMIUM FUND I, OAK XI AND THE OTHER PARTICIPANTS NAMED HEREIN STRONGLY ADVISE ALL STOCKHOLDERS OF THE COMPANY TO READ THE PROXY STATEMENT AND OTHER PROXY MATERIALS AS THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION. SUCH PROXY MATERIALS WILL BE AVAILABLE AT NO CHARGE ON THE SEC’S WEB SITE AT HTTP://WWW.SEC.GOV. IN ADDITION, THE PARTICIPANTS IN THIS PROXY SOLICITATION WILL PROVIDE COPIES OF THE PROXY STATEMENT WITHOUT CHARGE, WHEN AVAILABLE, UPON REQUEST. REQUESTS FOR COPIES SHOULD BE DIRECTED TO THE PARTICIPANTS’ PROXY SOLICITOR.

The participants in the proxy solicitation are anticipated to be Series One, VIEX GP, LLC (“VIEX GP”), VIEX Capital Advisors, LLC (“VIEX Capital”), Eric Singer, Osmium Fund I, Osmium Capital II, LP (“Osmium Fund II”), Osmium Spartan, LP (“Osmium Fund III”), Osmium Diamond, LP (“Osmium Fund IV”), Osmium Partners, LLC (“Osmium Partners”), John H. Lewis, Oak XI, Oak Associates XI, LLC (“Oak Associates XI”), Oak Investment Partners XII, Limited Partnership (“Oak XII”), Oak Associates XII, LLC (“Oak Associates XII”), and Oak Management Corporation (“Oak Management”) Grace A. Ames, Bandel L. Carano, Edward F. Glassmeyer, Fredric W. Harman, Ann H. Lamont, Michael J. McConnell, and John Mutch.

As of the date hereof, Series directly owns 2,282,045 shares of Common Stock, par value $0.0001 per share, of the Company (the “Common Stock”). VIEX GP, as the general partner of Series One, may be deemed the beneficial owner of the 2,282,045 shares of Common Stock beneficially owned by Series One. VIEX Capital, as the investment manager of Series One, may be deemed the beneficial owner of the 2,282,045 shares of Common Stock beneficially owned by Series One. Mr. Singer, as the managing member of each of VIEX GP and VIEX Capital, may be deemed the beneficial owner of the 2,282,045 shares of Common Stock beneficially owned by Series One. As of the date hereof, Osmium Fund I directly owns 1,059,336 shares of Common, including 161,200 shares of Common Stock underlying certain call options currently exercisable. As of the date hereof, Osmium Fund II directly owns 433,574 shares of Common Stock, including 67,500 shares of Common Stock underlying certain call options currently exercisable. As of the date hereof, Osmium Fund III directly owns 438,954 shares of Common Stock, including 76,500 shares of Common Stock underlying certain call options currently exercisable. As of the date hereof, Osmium Fund IV directly owns 882,626 shares of Common Stock, including 69,800 shares of Common Stock underlying certain call options currently exercisable. Osmium Partners, as the general partner of each of Osmium, Osmium Fund II, Osmium Fund III and Osmium Fund IV, may be deemed the beneficial owner of the 2,814,490 shares of Common Stock beneficially owned in the aggregate by each of Osmium, Osmium Fund II, Osmium Fund III and Osmium Fund IV, including 375,000 shares of Common Stock underlying certain call options currently exercisable. As of the date hereof, Mr. Lewis directly owns 94,348 shares of Common Stock. Mr. Lewis, as the managing member of Osmium Partners may be deemed the beneficial owner of the 2,814,490 shares of Common Stock beneficially owned in the aggregate by each of Osmium, Osmium Fund II, Osmium Fund III and Osmium Fund IV, including 375,000 shares of Common Stock underlying certain call options currently exercisable. As of the date hereof, Oak XI directly owns 2,948,287 shares of Common Stock. Oak Associates XI, as the general partner of Oak XI, may be deemed the beneficial owner of the 2,948,287 shares of Common Stock beneficially owned by Oak XI. As of the date hereof, Oak XII directly owns 769,387 shares of Common Stock. Oak Associates XII, as the general partner of Oak XII, may be deemed the beneficial owner of the 769,387 shares of Common Stock beneficially owned by Oak XII. Oak Management, as the manager of each of Oak Associates XI and Oak Associates XII, may be deemed the beneficial owner of the 3,717,674 shares of Common Stock beneficially owned in the aggregate by Oak XI and Oak XII. Ms. Ames, as a managing member of Oak Associates XII, may be deemed the beneficial owner of the 769,387 shares of Common Stock beneficially owned Oak II. Messrs. Carano, Glassmeyer and Harman and Ms. Lamont, as managing members of each of Oak Associates XI and Oak Associates XII, may be deemed the beneficial owner of the 3,717,674 shares of Common Stock beneficially owned in the aggregate by Oak XI and Oak XII. As of the date hereof, Messrs. McConnell and Mutch do not own any shares of Common Stock of the Company.

¹ All per share figures are based on 35,800,651 shares of the Company’s common stock outstanding as of February 22, 2021 as reported in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission on February 25, 2021.
² Digital Marketplace peers such as ETSY, RBL, FTCH, SFIX, and WISH average 8.8x revenue multiples.
³ Digital Media peers such as FRNWF and JCOM average 5.5x revenue multiples.
⁴ 49% to 47% discount based on conservative high and low estimates for Digital Marketplace revenue multiple.

Media Contact: [email protected] 

●   DISH to utilize Nokia’s NetGuard suite for security automation and orchestration

7 April 2021

DALLAS, TX and LITTLETON, Colo.
– Nokia today announced that DISH has selected Nokia’s NetGuard solution to assist with securing the United States’ first cloud-native, Open RAN-based 5G wireless network. This partnership will enable DISH to safeguard 5G network slices, which will be provisioned to support enterprise and wholesale customers.

Each 5G network slice can extend from the device through the radio, access, transport and core networks to each application server, and every path can be isolated and secured. Nokia’s NetGuard Security suite will be deployed within a cloud-native environment to provide security services through slice-specific Service Level Agreements (SLAs).

DISH is deploying NetGuard to support the security orchestration, automation and response capabilities needed to rapidly scale its network and intelligently assess and resolve cyber incidents with minimal manual intervention.

DISH will support new business models with network slicing for both enterprise and wholesale customers. Nokia’s NetGuard security operations enable DISH to efficiently and accurately respond to evolving security threats using automated tools, extended analytics, integrated collaboration processes and an optimized user experience.

Marc Rouanne, Chief Network Officer, DISH, said: “Secure network slicing is a key differentiator of DISH’s 5G network, and as we deliver these capabilities to our customers, we will provide a new level of security for their services. Nokia delivers a suite of security tools needed to help our customers unleash the power of network slicing, giving them the security, speed and control they require for their businesses.”

Raghav Sahgal, Cloud and Network Services President at Nokia, said: “Nokia is pleased to have been selected by DISH to secure its products and services. We recognize DISH’s need to support its network assets and customers in a fully secure way. Nokia´s NetGuard security operations solutions are built for the new 5G architecture and to meet the performance demands of DISH’s cloud-native network.”

Resources

• Webpage: Nokia NetGuard Security Operations
• Webpage: Nokia Security Consulting
• YouTube: NetGuard Security Operations
• Demo Zone: NetGuard Security Operations
• Press release: DISH chooses Nokia cloud-native, 5G standalone Core software to build U.S. 5G network with scale, performance, and efficiency

About Nokia

We create technology that helps the world act together.

As a trusted partner for critical networks, we are committed to innovation and technology leadership across mobile, fixed and cloud networks. We create value with intellectual property and long-term research, led by the award-winning Nokia Bell Labs.

Adhering to the highest standards of integrity and security, we help build the capabilities needed for a more productive, sustainable and inclusive world.

About DISH

DISH Network Corporation is a connectivity company. Since 1980, it has served as a disruptive force, driving innovation and value on behalf of consumers. Through its subsidiaries, the company provides television entertainment and award-winning technology to millions of customers with its satellite DISH TV and streaming SLING TV services. In 2020, the company became a nationwide U.S. wireless carrier through the acquisition of Boost Mobile. DISH continues to innovate in wireless, building the nation’s first cloud native, OpenRAN-based 5G broadband network. DISH Network Corporation (NASDAQ: DISH) is a Fortune 250 company.

Media Inquiries

Nokia Communications
Phone: +358 10 448 4900
Email: [email protected]

DISH Corporate Communications
Email: [email protected]

TORONTO, April 07, 2021 (GLOBE NEWSWIRE) — Doctor recommended medical CBD supplier, Cannalogue, has announced a significant price reduction for medical cannabis patients across Canada. As part of its expanded Compassionate Care Program, Cannalogue has secured the lowest per gram price for medical cannabis in Canada at $1.96/gram. Additionally, eligible new patients will receive 20% off their first order upon completion of a medical assessment.

With the most inclusive qualification criteria in Canada, Cannalogue’s Compassionate Care Program provides discounts of 20-50% on a wide range of medical cannabis products such as dried flower, oils, capsules, and topicals. Qualified groups include frontline workers, seniors (aged 60+), veterans, Indigenous peoples, first responders, nurses, teachers, those facing financial strain due to COVID-19 work shortage/layoffs, individuals currently enrolled in a disability, federal or provincial assistance program, and individuals with annual incomes less than $70,000 per year.

“We are living in times of unprecedented financial need, where cost is the key determinant in health decisions,” says Cannalogue President and CEO, Dr. Mohan Cooray. “With the lack of reasonable coverage, Cannalogue is doing all that we can to help our patients, and today is a gigantic leap forward in the quest towards affordable medical cannabis access for all Canadians,” he says.

To learn more about Cannalogue’s COVID-19 Compassionate Care Program or to enroll, visit www.cannalogue.ca/compassionate-care

About Cannalogue

:

Based in Toronto, Cannalogue is a rapidly emerging global healthcare technology company that received Health Canada’s first direct-to-sales licence for medical cannabis. Cannalogue’s innovative technology provides a safe, controlled, and cost-effective online marketplace that is globally scalable into all medical cannabis markets.  Engineered by physicians, Cannalogue challenges the status quo and advocates on behalf of patients to educate medical professionals and government officials on the safety and benefits of medical cannabis as a viable treatment option to traditional therapies.

 

Media Contact:

Melanie Greco
Public Relations
647-456-2653
[email protected]

NEWTON, Mass., April 07, 2021 (GLOBE NEWSWIRE) — Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, today announced the appointment of Mark J. Fitzpatrick to its board of directors.

“Mark is an experienced industry executive, who has led financial strategy at biopharmaceutical companies across all stages of development,” said Louis Brenner, M.D., President and Chief Executive Officer of Allena Pharmaceuticals. “His extensive experience working with late-stage, rare disease companies will be particularly valuable as we continue to advance our ongoing Phase 3 URIROX-2 clinical trial and begin preparing for the potential launch of reloxaliase as a first-in-class treatment for enteric hyperoxaluria.”

Mr. Fitzpatrick brings over 30 years of operational and financial management experience to Allena. Most recently, he spent six years at Chiasma, Inc. where he served initially as Chief Financial Officer and subsequently President and Chief Executive Officer, and played an integral role in securing U.S. Food and Drug Administration (FDA) approval of MYCAPSSA® for the treatment of acromegaly. Prior to Chiasma, he served as Chief Financial Officer for several biopharmaceutical companies. In these roles, Mr. Fitzpatrick raised over $1.5 billion in both public and private equity and debt financings, and helped negotiate strategic collaborations with both large pharmaceutical companies and commercial contract manufacturers. Mr. Fitzpatrick began his career at Arthur Andersen LLP and holds a B.S. in Accounting from Boston College.

“I am delighted to join Allena’s board of directors,” said Mr. Fitzpatrick. “Based on the data generated to date and its unique mechanism of action, I believe reloxaliase has the potential to revolutionize the treatment of enteric hyperoxaluria, providing patients with the first therapeutic option specifically developed for their disease. I am eager to lend my expertise to help advance this program, while also supporting Allena in the development of its broader pipeline, including ALLN-346 for the treatment of patients with hyperuricemia and chronic kidney disease.”

In conjunction with Mr. Fitzpatrick’s appointment, Allena announced that board members James Topper, M.D., Ph.D., managing general partner at Frazier Healthcare and a founding member of the company’s board of directors since 2011, and Andrew A. F. Hack, M.D., Ph.D., a member of the company’s board of directors since 2018, will not stand for re-election at the Company’s annual meeting in June.

“On behalf of the entire Allena team, I want to thank Jamie and Andrew for their service,” said Alexey Margolin, Ph.D., Chairman of the Board of Allena Pharmaceuticals. “Jamie has been a supportive, committed member of Allena’s board since the inception of the company and we are grateful for his many years of dedication and guidance. Together, Jamie and Andrew have contributed many important insights, which have been instrumental in enabling Allena to expand its clinical-stage pipeline and pursue its vision of building a public, fully-integrated, patient-focused biopharmaceutcal company.”

About Allena Pharmaceuticals

Allena Pharmaceuticals, Inc. is a late-stage biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class, oral biologic therapeutics to treat patients with rare and severe metabolic and kidney disorders. Allena’s lead product candidate, reloxaliase, is currently being evaluated in a pivotal Phase 3 clinical program for the treatment of enteric hyperoxaluria, a metabolic disorder characterized by markedly elevated urinary oxalate levels and commonly associated with kidney stones, chronic kidney disease and other serious kidney disorders. Allena is also developing ALLN-346 for the treatment of hyperuricemia in the setting of gout and advanced chronic kidney disease, with a Phase 1 multiple-ascending dose study and a Phase 2a program planned for 2021.

Forward-Looking Statements

This release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including, without limitation, statements concerning the future composition of the Board of Directors. Any forward-looking statements in this press release are based on management’s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: market and other conditions, the timing for completion of Allena’s clinical trials of its product candidates, risks associated with obtaining, maintaining and protecting intellectual property; risks associated with Allena’s ability to enforce its patents against infringers and defend its patent portfolio against challenges from third parties; the risk of competition from other companies developing products for similar uses; risk associated with Allena’s financial condition and its need to obtain additional funding to support its business activities, including the future clinical development of reloxaliase and its ability to continue as a going concern; risks associated with Allena’s dependence on third parties; and risks related to the COVID-19 coronavirus. For a discussion of other risks and uncertainties, and other important factors, any of which could cause Allena’s actual results to differ from those contained in the forward-looking statements, see the section entitled “Risk Factors” in Item 1A of Part I of Allena’s Annual Report on Form 10-k for the period ended December 31, 2020, as well as discussions of potential risks, uncertainties and other important factors in Allena’s subsequent filings with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and Allena undertakes no duty to update this information unless required by law.

Investor Contact

Hannah Deresiewicz
Stern Investor Relations, Inc.
212-362-1200
[email protected]

Media Contact

Adam Daley
Berry & Company Public Relations
212-253-8881
[email protected]

PHILADELPHIA, April 07, 2021 (GLOBE NEWSWIRE) — Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases, today announced that Steven Nichtberger, M.D., President and Chief Executive Officer, will participate in a fireside chat at the 20th Annual Needham Healthcare Conference on Wednesday, April 14, 2021 at 3:00 p.m. ET.

A live webcast of the fireside chat will be available on the News and Events section of the company’s website at www.cabalettabio.com. Following the presentation, a replay of the webcast will be available on the website for 90 days.

About Cabaletta Bio

Cabaletta Bio is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies, and exploring their potential to provide a deep and durable, perhaps curative, treatment, for patients with B cell-mediated autoimmune diseases. The Cabaletta Approach to selective B cell Ablation (CABA) platform, in combination with Cabaletta’s proprietary technology, utilizes Chimeric AutoAntibody Receptor (CAAR) T cells that are designed to selectively bind and eliminate only specific autoantibody-producing B cells while sparing normal antibody-producing B cells, which are essential for human health. The Company’s lead product candidate, DSG3-CAART, is being evaluated in the DesCAARTes™ phase 1 clinical trial as a potential treatment for patients with mucosal pemphigus vulgaris, a prototypical B cell-mediated autoimmune disease. The FDA granted Fast Track Designation for DSG3-CAART in May 2020. For more information about the clinical trial, please see www.clinicaltrials.gov. The Company’s lead preclinical product candidate, MuSK-CAART, is in IND-enabling studies and is designed as a potential treatment for patients with MuSK-associated myasthenia gravis. For more information, visit www.cabalettabio.com.

Contacts:

Anup Marda
Chief Financial Officer
[email protected]

Sarah McCabe
Stern Investor Relations, Inc.
212-362-1200
[email protected]